Skip to content

Study · Non-randomized trial · n = 16 · 1995

2 results

Effect of thyroid status on the prolactin-releasing action of vasoactive intestinal peptide in humans: comparison with the action of thyrotropin-releasing hormone.

Watanobe H, Sasaki S

Neuroendocrinology1 Feb 1995Cited by 9 (Europe PMC)

PMID7753340 (opens in a new tab)DOI10.1159/000126842 (opens in a new tab)PepBankPUB-07753340
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with hyperthyroidism or hypothyroidism, an intravenous VIP bolus significantly stimulated prolactin secretion in both the dysthyroid and euthyroid states.

    In plain wordsIn patients with thyroid disease, a VIP injection raised prolactin levels, both before and after thyroid treatment.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseProlactin secretion after VIP bolus
    Study

    n = 16

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    100 micrograms · intravenous bolusAs given in this study (human).

    Source sentences

    Summary
    although the peptide was able to significantly stimulate PRL secretion during both the dysthyroid and euthyroid states of hyper- and hypothyroid patients
    1 context sentence
    Summary · context
    Eight female patients with Graves' disease and 8 females with chronic thyroiditis received intravenous bolus injections of VIP (100 micrograms) and TRH (500 micrograms) 2-3 days apart from each other, during both the dysthyroid and euthyroid (attained by medical treatment) states.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with hyperthyroidism or hypothyroidism, prolactin responsiveness to VIP was essentially the same regardless of thyroid status.

    In plain wordsIn patients with thyroid disease, the prolactin rise after VIP was about the same whatever their thyroid state.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeProlactin responsiveness to VIP by thyroid status
    Study

    n = 16

    Comparator
    Euthyroid state
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    100 micrograms · intravenous bolusAs given in this study (human).

    Source sentences

    Summary
    PRL responsiveness to VIP was essentially the same regardless of thyroid status.(ABSTRACT TRUNCATED AT 250 WORDS)
    1 context sentence
    Summary · context
    Eight female patients with Graves' disease and 8 females with chronic thyroiditis received intravenous bolus injections of VIP (100 micrograms) and TRH (500 micrograms) 2-3 days apart from each other, during both the dysthyroid and euthyroid (attained by medical treatment) states.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.